DEM Bio website screenshot

DEM Bio

DEM BioPharma is a Cambridge, Massachusetts biotechnology company developing first-in-class cancer therapeutics that target the signals solid tumors use to evade immune destruction. The company pioneers next-generation macrophage and innate-immune immunotherapies discovered through its proprietary CHoMP (Co-culture with Human Myeloid Phagocytes) functional-genomics platform, which uses CRISPR-based screening to identify novel "don't-eat-me" and activating targets on myeloid cells. DEM launched in 2022 with $70M in Series A financing and is backed by Longwood Fund, Emerson Collective, Pfizer Ventures, Astellas, and Insight Partners. Added to the API Evangelist network as a portfolio-company profile; DEM publishes no public developer or API surface at this time.

DEM Bio is profiled on the APIs.io network. Tagged areas include Company, Biotech Therapeutics, Oncology, Immunotherapy, and Cancer.

DEM Bio’s developer surface includes engineering blog, support, and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotech TherapeuticsOncologyImmunotherapyCancerCRISPRDrug DiscoveryFunctional GenomicsMacrophage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/dem-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Dem Bio Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: dem-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/dem-bio.png
name: DEM Bio
description: DEM BioPharma is a Cambridge, Massachusetts biotechnology company developing first-in-class cancer therapeutics
  that target the signals solid tumors use to evade immune destruction. The company pioneers next-generation macrophage and
  innate-immune immunotherapies discovered through its proprietary CHoMP (Co-culture with Human Myeloid Phagocytes) functional-genomics
  platform, which uses CRISPR-based screening to identify novel "don't-eat-me" and activating targets on myeloid cells. DEM
  launched in 2022 with $70M in Series A financing and is backed by Longwood Fund, Emerson Collective, Pfizer Ventures, Astellas,
  and Insight Partners. Added to the API Evangelist network as a portfolio-company profile; DEM publishes no public developer
  or API surface at this time.
url: https://raw.githubusercontent.com/api-evangelist/dem-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotech Therapeutics
- Oncology
- Immunotherapy
- Cancer
- CRISPR
- Drug Discovery
- Functional Genomics
- Macrophage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/dem-bio-domain-security.yml
- type: Website
  url: https://dembiopharma.com/
- type: Blog
  url: https://dembiopharma.com/news.html
- type: Support
  url: https://dembiopharma.com/contact.html
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence